RESUMO
OBJECTIVES: Our study aimed to investigate the effects of alprostadil and Salvia miltiorrhiza extract on myocardial ischemia-reperfusion injury (IRI) and related underlying molecular mechanisms. METHODS: A myocardial IRI model was established in Wistar rats via surgical ligation of the left anterior descending coronary artery followed by loosening of the occlusion. The rats were divided into four groups: saline, sham, alprostadil, and S. miltiorrhiza. Rats in the saline and sham groups were injected with normal saline by tail vein once daily for 10 consecutive days. Rats in the S. miltiorrhiza and alprostadil groups were injected with S. miltiorrhiza extract (20 µg/kg) or alprostadil. Histological differences in myocardial tissues between rats in the sham group and in the myocardial IRI model were observed by hematoxylin and eosin staining. India ink perfusion was used to quantify the number of capillary microvessels. Real-time quantitative reverse transcription polymerase chain reaction was used to determine serum expression levels of soluble intercellular adhesion molecule (sICAM), soluble vascular adhesion molecule (sVCAM), CD11b and CD18. RESULTS: The alprostadil and S. miltiorrhiza groups had significantly higher numbers of microvessels than the saline group. Serum sICAM and sVCAM expression was significantly reduced in the alprostadil and S. miltiorrhiza groups. Meanwhile, sICAM and sVCAM in the alprostadil group were markedly lower than in the S. miltiorrhiza group. Moreover, the alprostadil group had markedly lower mRNA expression of CD11b and CD18, which were clearly lower than in the S. miltiorrhiza group. CONCLUSION: Alprostadil may have cardioprotective effects for myocardial IRI, with down-regulated expression of sICAM, sVCAM, CD11b, and CD18.
RESUMO
Lithium-sulfur (Li-S) battery is an important candidate for next-generation energy storage. However, the reaction between polysulfide and lithium (Li) anode brings poor cycling stability, low Coulombic efficiency, and Li corrosion. Herein, we report a Li protection technology. Li metal was treated in crown ether containing electrolyte, and thus, treated Li was further used as the anode in Li-S cell. Due to the coordination between Li+ and crown ether, a Li+-permeable film can be formed on Li, and the film is proved to be able to block the detrimental reaction between Li anode and polysulfide. By using the Li anode pretreated in 2 wt % B15C5-containing electrolyte, Li-S cell exhibits significantly improved cycling stability, such asâ¼900 mAh g-1 after 100 cycles, and high Coulombic efficiency of>93%. In addition, such effect is also notable when high S loading condition is applied.
RESUMO
OBJECTIVE: To investigate the value of panel fluorescence in situ hybridization for detection of genomic aberrations in chronic lymphocytic leukemia(CLL). METHODS: Five types of fluorescein-labelled DNA probes including centromeric probes for chromosomes 3,12 and 18, and two sequence-specific probes D13S272 for 13q14.3 and ATM for 11q23 were used to perform fluorescence in situ hybridization (FISH) assays in 22 patients with CLL. Its results were compared with that of conventional cytogenetic (CC) examination in order to ascertain which method is more sensitive and reliable for the detection of chromosomal and genomic abnormalities in CLL. RESULTS: On CC examination, only 8 cases (36.3%) were found to have chromosomal abnormalities including sole trisomy 12 in 3 cases, simultaneous trisomies 3 and 12 in one case, simultaneous trisomies 3, 12 and 18 in one case, translocation between chromosomes 5 and 15 in one case, deletion of 13q14.3 in one case, 3q- and 18p+ in one case, 4q+ and 13q- in one case, whereas on panel FISH assay, 15 cases (68.1%) were found to have genomic aberrations including trisomy 3 in 4 cases, trisomy 12 in 6 cases, trisomy 18 in one case, deletion of 13q14.3 in 8 cases, deletion of 11q23 in 6 cases. CONCLUSION: Panel FISH is a useful method for detection of genomic aberration in CLL, if combined with CC, it can obviously enhance the detection rate of chromosomal abnormalities in CLL.